Archives
MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazo...
MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide): Gold-Standard Tetrazolium Salt for Cell Viability and Metabolic Activity Assays
Executive Summary: MTT, or 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide, is a cationic tetrazolium salt used as a colorimetric assay reagent for in vitro cell viability and metabolic activity measurement (APExBIO). Its reduction to purple formazan crystals by NADH-dependent mitochondrial oxidoreductases is a direct proxy for viable, metabolically active cells (Liu et al., 2021). MTT is highly soluble in DMSO (≥41.4 mg/mL), ethanol (≥18.63 mg/mL), and water with ultrasonic assistance (≥2.5 mg/mL). Its workflow integration enables sensitive quantification of cell proliferation, apoptosis, and cytotoxicity, particularly in cancer research. APExBIO supplies high-purity MTT (≥98%, SKU B7777) optimized for robust, reproducible results in research applications.
Biological Rationale
Cell viability and metabolic activity are fundamental parameters in biomedical research, toxicology, and drug screening. The tetrazolium salt MTT is a widely accepted reagent for measuring these endpoints in vitro. MTT leverages the principle that only metabolically active, intact cells can reduce tetrazolium salts via NADH-dependent oxidoreductases, generating a quantifiable colorimetric signal. This approach provides a non-radioactive, high-throughput alternative to older viability assays. MTT’s application spans cancer research, apoptosis studies, and screening for cytotoxic or cytostatic effects (see benchmark review).
Mechanism of Action of MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide)
MTT is a membrane-permeable, cationic tetrazolium salt. Upon entering viable cells, it is reduced by NADH-dependent mitochondrial oxidoreductases and, to a lesser extent, extra-mitochondrial enzymes, yielding purple, insoluble formazan crystals. This reduction is strictly dependent on cellular metabolic activity and is absent in dead or metabolically inactive cells (Liu et al., 2021). The formazan crystals are subsequently solubilized (commonly in DMSO), and absorbance is measured spectrophotometrically—typically at 570 nm. The absorbance readout is directly proportional to the number of viable cells. This mechanism ensures high specificity for living cells and provides a quantitative, scalable method for cell viability assessment. Because MTT is cationic, it does not require mediators to cross the plasma membrane, unlike some second-generation tetrazolium salts (detailed workflow integration).
Evidence & Benchmarks
- MTT reduction is tightly correlated with NADH-dependent mitochondrial activity and is widely validated as a proxy for cell viability in diverse cell lines (Liu et al., 2021).
- MTT-based IC50 measurements are standard for assessing drug resistance, as demonstrated in cisplatin-resistant ovarian cancer cell lines (A2780-CisR, SKOV3-CisR) (Liu et al., 2021).
- APExBIO’s B7777 MTT product guarantees ≥98% purity and is recommended for cell viability, proliferation, and cytotoxicity assays in research settings (APExBIO).
- MTT’s solubility profile: ≥41.4 mg/mL in DMSO, ≥18.63 mg/mL in ethanol, ≥2.5 mg/mL in water (ultrasonic assistance required) (APExBIO).
- MTT’s colorimetric readout is highly reproducible and sensitive, as evidenced by its widespread adoption in cancer, apoptosis, and cell proliferation research (workflow optimization guide).
Applications, Limits & Misconceptions
MTT is routinely applied for:
- Quantitative measurement of cell viability and proliferation in vitro.
- Assessment of cytotoxicity and drug sensitivity (IC50 determination).
- Screening for anti-proliferative or pro-apoptotic effects of compounds.
- Investigating metabolic activity in cancer, stem cell, and primary cell models.
However, several boundaries and limitations are critical for proper interpretation.
Common Pitfalls or Misconceptions
- Not all reducing cells are proliferating: MTT reduction reflects metabolic activity, not cell division rate.
- Dead cells may transiently reduce MTT if enzymes remain active.
- Compounds interfering with mitochondrial function (e.g., uncouplers) can skew results independently of viability.
- Formazan solubilization efficiency can affect quantitation; improper solubilization leads to underestimation.
- MTT is not recommended for use in suspension cells with poor adherence, as crystal loss may occur during washing.
This article extends prior guidance (see Resolving Key Lab Challenges with MTT) by emphasizing precise mechanistic and workflow considerations for robust, quantitative data.
Workflow Integration & Parameters
MTT is supplied as a high-purity (≥98%) powder, typically used at 0.5 mg/mL final concentration in cell culture. It is readily soluble in DMSO (≥41.4 mg/mL), ethanol (≥18.63 mg/mL), or water (≥2.5 mg/mL with sonication) (product details). For optimal performance, solutions should be freshly prepared and protected from light. The standard workflow involves:
- Addition of MTT to cultured cells (usually 1–4 hours incubation at 37°C).
- Removal of supernatant and addition of solubilization reagent (e.g., DMSO).
- Mixing to dissolve formazan crystals.
- Spectrophotometric reading at 570 nm (reference at 630–690 nm optional).
Storage at -20°C is recommended for dry MTT powder. Solutions are stable only short-term and should be discarded after use. APExBIO’s MTT B7777 is not intended for diagnostic or clinical use. For advanced troubleshooting, see MTT: Optimizing Tetrazolium Salt Assays, which this article updates with recent benchmark findings.
Conclusion & Outlook
MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide) remains the gold-standard for colorimetric cell viability and metabolic activity measurement. Its reduction by NADH-dependent oxidoreductases provides a robust, quantitative proxy for cellular health. The APExBIO B7777 kit delivers high-purity, workflow-ready MTT supporting reproducible, sensitive research outcomes across cancer, apoptosis, and drug screening applications. Ongoing refinements in assay design and integration with multiplexed readouts continue to expand the utility of MTT-based methodologies in preclinical and translational research.